Hyponatraemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:54 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hyponatraemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Empagliflozin in Patients with Euvolemic and Hypervolemic Hyponatremia https://clinicaltrials.eu/trial/study-on-the-effects-of-empagliflozin-in-patients-with-euvolemic-and-hypervolemic-hyponatremia/ Wed, 29 Apr 2026 15:04:42 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-empagliflozin-in-patients-with-euvolemic-and-hypervolemic-hyponatremia/ This clinical trial is focused on studying a condition called hyponatremia, which occurs when there is a low level of sodium in the blood. The study will explore the effects of a medication called empagliflozin, also known by its brand name Jardiance. Empagliflozin is a type of drug known as an SGLT2 inhibitor, which is typically used to help control blood sugar levels in people with diabetes. In this study, it will be used to see if it can help increase sodium levels in patients with hyponatremia.

The purpose of the study is to determine if taking empagliflozin once daily can lead to a greater increase in blood sodium levels over a short period of 4 days and a longer period of 30 days, compared to a placebo. Participants in the study will be randomly assigned to receive either empagliflozin or a placebo. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will have their sodium levels monitored regularly. They will also be assessed for changes in their overall well-being, quality of life, and any symptoms related to hyponatremia, such as headache, dizziness, and nausea. The study will also track other health indicators, including blood pressure, heart rate, and body weight. The trial aims to provide valuable insights into whether empagliflozin can be an effective treatment for improving sodium levels in patients with hyponatremia.

]]> Study on Urea for Treating Low Sodium Levels in Patients with Brain Hemorrhage https://clinicaltrials.eu/trial/study-on-urea-for-treating-low-sodium-levels-in-patients-with-brain-hemorrhage/ Wed, 29 Apr 2026 15:02:29 +0000 https://clinicaltrials.eu/trial/study-on-urea-for-treating-low-sodium-levels-in-patients-with-brain-hemorrhage/ This clinical trial is focused on studying the treatment of hyponatremia, a condition characterized by low sodium levels in the blood, which can occur during a subarachnoid hemorrhage. A subarachnoid hemorrhage is a type of stroke caused by bleeding on the surface of the brain. The treatment being tested in this study is Urea, which is administered as an oral powder. Urea is a compound that can help increase sodium levels in the blood.

The purpose of the study is to demonstrate the effectiveness of urea in correcting persistent hyponatremia, even when other management strategies have been adequately applied. Participants in the study will receive either urea or a placebo, which is a substance with no active medication. The study will monitor changes in sodium levels before and after the treatment period, which lasts up to five days. The study will also look at how much sodium intake is needed to correct the sodium levels, the mechanism of action of urea, and any potential side effects.

Throughout the study, researchers will assess the impact of the treatment on the length of hospital stay and the neurological outcomes three months after starting the treatment. They will also evaluate how quickly the sodium levels are corrected and whether the correction persists 48 hours after stopping the treatment. This trial aims to provide valuable insights into the management of hyponatremia in patients with subarachnoid hemorrhage.

]]> Study on Using Desmopressin Acetate Trihydrate to Prevent Sodium Overcorrection in Patients with Severe Hyponatremia https://clinicaltrials.eu/trial/study-on-using-desmopressin-acetate-trihydrate-to-prevent-sodium-overcorrection-in-patients-with-severe-hyponatremia/ Wed, 29 Apr 2026 14:29:21 +0000 https://clinicaltrials.eu/trial/study-on-using-desmopressin-acetate-trihydrate-to-prevent-sodium-overcorrection-in-patients-with-severe-hyponatremia/ This clinical trial is focused on studying the condition known as severe hyponatremia, which occurs when there is a dangerously low level of sodium in the blood. This can lead to serious health issues, especially if the sodium level rises too quickly. The trial aims to explore the use of a medication called DDAVP (also known as desmopressin acetate trihydrate) to prevent the rapid increase of sodium levels in patients with severe hyponatremia. The study will also involve the use of other substances like sodium chloride, potassium chloride, and glucose solutions, which are commonly used in medical treatments to manage fluid and electrolyte balance in the body.

The purpose of this study is to determine if using DDAVP can help control the sodium levels in the blood more effectively during the first 48 hours of treatment. This is important because a rapid increase in sodium can lead to complications such as brain damage. The study will be conducted in a hospital setting, where participants will receive either DDAVP or a placebo, along with other standard treatments. The trial will monitor the sodium levels and other health indicators to assess the effectiveness of the treatment.

Participants in the study will be closely observed for any changes in their condition, including the presence of neurological symptoms like seizures or confusion. The study will also track the length of hospital stay and any potential side effects. By the end of the study, researchers hope to gather valuable information on how to better manage severe hyponatremia and improve patient outcomes. This research could lead to more effective treatment strategies for those at risk of rapid sodium level changes.

]]>